| References |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Personal Finance > Fee Only Financial Advisors |
|
References - Fee Only Financial Advisors
“Unless you have a definite, precise, clearly set goals, you are not going to realize the maximum potential that lies within y According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ou.” - Zig Ziglar It is extremely trendy in today's financial market to hire a “fee only” financial advisor. This a great al ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ernative for investors who want to invest on their own but need advice from time to time. This type of advisor is paid by the lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. hour or a lump sum fee and not by commission resulting from the buying and selling of stocks. An investor benefits from this here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe type of arrangement in many ways. You do not have to question the motives of “fee only” financial advisor because he is not g d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ing to get paid anymore for suggesting you buy or sell stock. Their services usually include reviewing or creating investment ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc portfolios. Many financial advisors are also educated in a number of different areas including real estate, higher education easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi financing, retirement, and taxes. Most investors do not realize that the majority of brokerages and financial advisors do not nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically provide their services for free. Often payment details are never discussed until after stocks are bought and sold. The inves and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ tor assumes that their advice is free. Their fees come right out of your account. Commission based advisors receive large ch ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi nks of what you are investing sometimes close to 5%. When hiring a “fee only” advisor you know his hourly rate right up fron ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a , and he gets paid only for the amount of time he puts into working for you. The reason why “fee only” financial investors ar dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod e so popular is because they offer the best of both worlds. They allow the financial planner make money while still being abl cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin to do what is right for their client. Investors can have more confidence in this type of advisor because their paid is a set tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen fee and there will be no pressure to sell or buy stocks. Remember, commission based advisors get paid no matter what. If you t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel are losing money in the stock market, they are still making money from you buying and selling stock. If the majority of your ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust investments are long term and you do not foresee buying or selling stock regularly then a commission based financial advisor m y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products ght work well for you. However, if you work for a company that offers 401k's, they will often have a financial consultant whi . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ch will work with you for free. They are being paid by the company to field questions about investments and the stock market. elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip Take advantage of the benefits your job offers and consult a financial advisor, today, with all of your investment questions tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Mentoring: A Partnership for Success Search Engine Optimisation - Simplified (Part I)
|